Anas Ibraheem: Apixaban Shows Superior Safety in Acute VTE While Matching Rivaroxaban Efficacy
Anas Ibraheem, Medical Oncology Fellow at The London Clinic, shared a Abdulrahman Nasiri‘s post on LinkedIn:
“A recent gem from NEJM, COBRRA trial: an international trial with a prospective, randomised, open-label, and blinded end-point design clear the long-standing debate of apixaban vs rivaroxaban (head-to-head) bleeding risk when a decision to start anticoagulants for acute VTE is taken.
A wonderful illustration of those results in the attached post. ”
Quoting Abdulrahman Nasiri‘s post:
“In preparation for my upcoming Grand Rounds presentation, I’ve put together these slides translating the recent COBRRA trial (NEJM 2026) titled:
‘Settling the DOAC Debate in Acute VTE’
For years, major clinical guidelines haven’t recommended one DOAC over another due to a lack of head-to-head randomized trials.
Here is the most important concepts and the clinical shift this trial brings to our practice:
- Identical Efficacy: Both apixaban and rivaroxaban demonstrated an identical approximately one percent rate of recurrent VTE.
- Superior Safety: Apixaban cut the risk of clinically relevant bleeding by more than half and drove an 84 percent reduction in major bleeding.
- The Dosing Hypothesis: Why the difference? The bleeding divergence explodes in the first 3 weeks.
Rivaroxaban requires a high-dose induction phase that is three times longer than apixaban (twenty-one days versus seven days).
I am sharing the presentation here, please feel free to use and adapt these slides for your own reference, clinical discussions, or teaching! ”
Stay updated with Hemostasis Today.
-
Apr 1, 2026, 13:29Kevin Shortall: Life-Saving Blood Donation Amid Ireland’s Shortage
-
Apr 1, 2026, 13:12Kalyan Roy: Wrong Blood in Tube – A Small Error with Life-Threatening Consequences
-
Apr 1, 2026, 12:37Yves Bikorimana։ Normal MCV Doesn’t Always Mean Normal RBCs
-
Apr 1, 2026, 12:09Maxime Dely: Helping Patients Live More Freely with Sickle Cell Disease
-
Apr 1, 2026, 11:53Sharmila Manian: The Mystery of the Positive Direct Coombs Test in Donors
-
Apr 1, 2026, 11:46Wolfgang Miesbach: A Paradigm Shift in the Management of Acquired Haemophilia A
-
Apr 1, 2026, 11:46Cedric Hermans: Revisiting the Role of Factor VIII in Haemophilia A in 2026 on E-Learning Insights
-
Apr 1, 2026, 11:36Jim Hoffman: Dysregulated NETosis as a Key Driver of Neuro–Cardiac–Metabolic Health Dysfunction
-
Mar 31, 2026, 16:05Happy National Doctors’ Day to All Physicians Making a Difference – ASH